Health & Wellbeing

Ahead of a FDA advisory panel meeting, drugmaker Merck has revealed final analysis data from a Phase 3 trial testing its oral antiviral pill against COVID-19. The new data reveals the treatment is significantly less effective than early indications.

The World Health Organization has recently identified a new SARS-CoV-2 variant of concern. Emerging out of southern Africa the variant has been dubbed Omicron and initial analysis indicates it carries a large number of novel mutations.

As we age, our eyesight naturally declines, but a new study has found just three minutes of exposure to 670-nanometer red light in the morning can help deteriorating vision, improving color contrast vision by nearly 20 percent.

A new study has explored how physical activity at the outset of a dietary fasting period can accelerate a shift to ketosis, a metabolic state associated with the burning of stored fats and weight loss.

New follow-up data from Pfizer’s COVID-19 vaccine trial in 12 to 15 year olds show robust efficacy up to four months after the two-dose protocol. The data reveals the vaccine is 100 percent effective at preventing symptomatic SARS-CoV-2 infection.

US regulators have authorized a 3rd COVID-19 vaccine booster for adults over age 18. The recommendations simplify the health advice and infectious disease expert Anthony Fauci urges boosters for all those who are six months beyond their second dose.

A new study has explored the impacts of exercise on sufferers of arthritis, and shown how the gut microbiome and cannabis-like substances produced by the body play an important mediatory role in driving anti-inflammatory effects.

The results have been revealed from a study testing an algorithm designed to detect irregular heart rhythms using data from wearables. Enrolling nearly half a million subjects, the study detected undiagnosed atrial fibrillation in 98 percent of cases.

New data has shown a 3rd COVID-19 vaccine dose significantly boosts protection against symptomatic disease. The findings indicate a 3rd dose may become part of the standard coronavirus vaccine protocol, administered around six months after a 2nd dose.

A new study in The Lancet is offering the first peer-reviewed and published data on the efficacy of Covaxin, a COVID-19 vaccine developed in India. The vaccine was 77.8 percent effective at preventing symptomatic COVID-19 in a Phase 3 clinical trial.

It's well established that exercise can be good for our mental health. Now a new study has uncovered a relationship between the intensity of physical activity and relief from symptoms of anxiety, with those working up the most sweat found to benefit the most.

A new KFF survey has found 78 percent of Americans believe, or are uncertain about, at least one piece of COVID-19 misinformation. The survey also found more than one third of those polled believe the government is exaggerating the number of COVID-19 deaths.